Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991. View on euronews ...

As Heart Month reminds us of the critical need to protect our cardiovascular and metabolic (CVM) health, Novo Nordisk Philippines and the Philippine College of Endocrinology, Diabetes, and ...

Profit and prosper with the best of expert advice - straight to your e-mail. Novo Nordisk has underperformed the broad market on the price charts over the past 12 months, down 17% vs the S&P 500's ...

GLP-1 diabetes drugs like Ozempic may modestly reduce cancer risks Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

WASHINGTON — Sen. Bernie Sanders, I-Vt., on Tuesday extracted a meager commitment from Novo Nordisk CEO Lars Fruergaard Jørgensen to meet with pharmacy benefits managers to discuss lowering the ...

Novo Nordisk NOVO.B-2.96%decrease; red down pointing triangle shares rallied Wednesday as investors breathed a sigh of relief after first-quarter earnings beat expectations and the company’s ...

Novo Nordisk NOVO.B-0.78%decrease; red down pointing triangle said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford ...

Novo Nordisk, the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. But the Danish pharmaceutical company's origins were motivated by ...

LONDON, April 24 (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk (NOVOb.CO), opens new tab has raised its annual sales guidance several times a year.

A federal court judge ruling leaves in place an FDA determination that shortages of the Novo Nordisk drugs Wegovy and Ozempic are resolved. Consequently, compounding pharmacies must stop making ...